Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Rexlemestrocel-L by Mesoblast for Hypoplastic Left Heart Syndrome: Likelihood of Approval
Rexlemestrocel-L is under clinical development by Mesoblast and currently in Phase II for Hypoplastic Left Heart Syndrome. According to GlobalData,...